Omeros Corporation (NASDAQ:OMER - Get Free Report) CAO David Borges sold 906 shares of Omeros stock in a transaction on Monday, August 24th. The stock was sold at an average price of $19.10, for a total transaction of $17,304.60. Following the transaction, the chief accounting officer directly owned 5,906 shares in the company, valued at approximately $112,804.60. This represents a 13.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Omeros Stock Down 0.2%
OMER opened at $19.28 on Wednesday. Omeros Corporation has a 12 month low of $3.94 and a 12 month high of $19.65. The company has a fifty day simple moving average of $12.12 and a 200 day simple moving average of $11.87. The stock has a market cap of $1.40 billion, a P/E ratio of 15.06 and a beta of 2.54.
Omeros (NASDAQ:OMER - Get Free Report) last issued its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.27) by $0.29. The business had revenue of $28.53 million for the quarter, compared to analyst estimates of $12.69 million. On average, equities research analysts expect that Omeros Corporation will post -0.37 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Omeros
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. bought a new stake in Omeros during the 2nd quarter worth about $57,484,000. Vanguard Group Inc. grew its holdings in shares of Omeros by 19.9% in the 4th quarter. Vanguard Group Inc. now owns 4,013,315 shares of the biopharmaceutical company's stock valued at $68,929,000 after acquiring an additional 666,357 shares in the last quarter. UBS Group AG grew its holdings in shares of Omeros by 213.5% in the 4th quarter. UBS Group AG now owns 2,222,982 shares of the biopharmaceutical company's stock valued at $38,180,000 after acquiring an additional 1,513,893 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Omeros by 6.3% in the fourth quarter. Geode Capital Management LLC now owns 1,631,350 shares of the biopharmaceutical company's stock valued at $28,026,000 after acquiring an additional 95,979 shares during the last quarter. Finally, State Street Corp raised its holdings in Omeros by 26.9% during the fourth quarter. State Street Corp now owns 1,573,526 shares of the biopharmaceutical company's stock worth $27,025,000 after acquiring an additional 333,798 shares in the last quarter. 48.79% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
Several equities analysts recently issued reports on the company. Weiss Ratings upgraded Omeros from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Wednesday, August 5th. HC Wainwright reiterated a "buy" rating on shares of Omeros in a report on Monday, July 27th. Zacks Research lowered shares of Omeros from a "strong-buy" rating to a "hold" rating in a report on Monday, July 13th. Finally, Wall Street Zen raised shares of Omeros from a "hold" rating to a "buy" rating in a research report on Saturday, August 15th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Omeros has an average rating of "Moderate Buy" and an average price target of $38.00.
Get Our Latest Stock Analysis on Omeros
Omeros Company Profile
(
Get Free Report)
Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company's research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros's portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.
Omeros's first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
